Liraglutide's effect on food intake in obese subjects to be assessed in 6-week RCT

Obesity is a chronic disease with significant health implications, often driven by dysregulated food intake. Current weight management strategies, including lifestyle interventions and pharmacotherapy, aim to reduce caloric consumption. Liraglutide, a GLP-1 receptor agonist, is approved for weight management, but the precise quantification of its impact on food intake in an obese population over a defined period warrants further investigation to optimize treatment protocols and understand its mechanism of action.

This will be a randomized, double-blind, placebo-controlled, 2-arm, parallel-group methodology study. Obese subjects will be randomized 1:1 to receive either liraglutide 3.0 mg or placebo, administered subcutaneously once-daily for 6 weeks. The primary endpoint is the assessment of food intake. This design aims to specifically quantify the effect of liraglutide on food intake in this population.

As this is a methodology study describing a planned trial, specific findings and numerical results are not yet available. The study aims to generate data on the effect of liraglutide on food intake in obese subjects over a 6-week period. Future results are anticipated to provide quantitative insights into how liraglutide influences caloric consumption and contributes to weight management.